Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Moxifloxacin resistance: intrinsic to antibiotic or related to mutation?

Agarwal T, Jhanji V, Satpathy G, Nayak N, Chawla B, Tandon R, Titiyal JS.

Optom Vis Sci. 2012 Dec;89(12):1721-4. doi: 10.1097/OPX.0b013e31827717d4.

PMID:
23142880
2.

Fourth-generation fluoroquinolone-resistant bacterial keratitis.

Jhanji V, Sharma N, Satpathy G, Titiyal J.

J Cataract Refract Surg. 2007 Aug;33(8):1488-9.

PMID:
17662450
3.

Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers.

Shah VM, Tandon R, Satpathy G, Nayak N, Chawla B, Agarwal T, Sharma N, Titiyal JS, Vajpayee RB.

Cornea. 2010 Jul;29(7):751-7. doi: 10.1097/ICO.0b013e3181ca2ba3.

PMID:
20489580
4.

In vitro susceptibility of bacterial keratitis isolates to fourth-generation fluoroquinolones.

Chawla B, Agarwal P, Tandon R, Titiyal JS, Sharma N, Agarwal T, Navak N, Satpathy G.

Eur J Ophthalmol. 2010 Mar-Apr;20(2):300-5.

PMID:
19924668
5.

Gatifloxacin, moxifloxacin, and balofloxacin resistance due to mutations in the gyrA and parC genes of Staphylococcus epidermidis strains isolated from patients with endophthalmitis, corneal ulcers and conjunctivitis.

Betanzos-Cabrera G, Juárez-Verdayes MA, González-González G, Cancino-Díaz ME, Cancino-Díaz JC.

Ophthalmic Res. 2009;42(1):43-8. doi: 10.1159/000219684. Epub 2009 May 28.

PMID:
19478540
6.

[Antibiotic susceptibility patterns of bacteria isolated from keratitis and intraocular infections at Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia].

Galvis V, Tello A, Guerra A, Acuña MF, Villarreal D.

Biomedica. 2014 Apr;34 Suppl 1:23-33. doi: 10.1590/S0120-41572014000500004. Spanish.

7.

Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial.

Constantinou M, Daniell M, Snibson GR, Vu HT, Taylor HR.

Ophthalmology. 2007 Sep;114(9):1622-9.

PMID:
17822972
8.

Evaluation of moxifloxacin 0.5% in treatment of nonperforated bacterial corneal ulcers: a randomized controlled trial.

Sharma N, Goel M, Bansal S, Agarwal P, Titiyal JS, Upadhyaya AD, Vajpayee RB.

Ophthalmology. 2013 Jun;120(6):1173-8. doi: 10.1016/j.ophtha.2012.11.013. Epub 2013 Feb 15.

PMID:
23415776
9.

[In vitro antibiotic susceptibility to fluoroquinolones].

Wong CA, Galvis V, Tello A, Villareal D, Rey JJ.

Arch Soc Esp Oftalmol. 2012 Mar;87(3):72-8. doi: 10.1016/j.oftal.2011.06.023. Epub 2011 Dec 29. Spanish.

PMID:
22423655
11.

In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection.

Kowalski RP, Kowalski TA, Shanks RM, Romanowski EG, Karenchak LM, Mah FS.

Cornea. 2013 Jun;32(6):830-4. doi: 10.1097/ICO.0b013e318268d6f4.

12.

In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.

Stroman DW, Dajcs JJ, Cupp GA, Schlech BA.

Surv Ophthalmol. 2005 Nov;50 Suppl 1:S16-31. Review.

PMID:
16257308
13.

Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery.

Moshirfar M, Mirzaian G, Feiz V, Kang PC.

J Cataract Refract Surg. 2006 Mar;32(3):515-8.

PMID:
16631067
14.

Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens.

Callegan MC, Ramirez R, Kane ST, Cochran DC, Jensen H.

Adv Ther. 2003 Sep-Oct;20(5):246-52.

PMID:
14964344
15.

Moxifloxacin for bacterial keratitis.

Rosenberg J, Eisen L, Kim J.

Ophthalmology. 2008 Jun;115(6):1103; author reply 1103. doi: 10.1016/j.ophtha.2007.11.020. No abstract available.

PMID:
18519075
16.

Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India.

Oldenburg CE, Lalitha P, Srinivasan M, Rajaraman R, Ravindran M, Mascarenhas J, Borkar DS, Ray KJ, Zegans ME, McLeod SD, Porco TC, Lietman TM, Acharya NR.

Ophthalmic Epidemiol. 2013 Jun;20(3):155-8. doi: 10.3109/09286586.2013.790978. Epub 2013 May 10.

17.

Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.

Reddy AK, Garg P, Alam MR, Gopinathan U, Sharma S, Krishnaiah S.

Eye (Lond). 2010 Jan;24(1):170-4. doi: 10.1038/eye.2009.29. Epub 2009 Feb 20.

PMID:
19229279
18.

Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.

Alexandrakis G, Alfonso EC, Miller D.

Ophthalmology. 2000 Aug;107(8):1497-502.

PMID:
10919897
19.

Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.

Deramo VA, Lai JC, Fastenberg DM, Udell IJ.

Am J Ophthalmol. 2006 Nov;142(5):721-5. Epub 2006 Sep 20.

PMID:
16989762
20.

Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.

Sanders ME, Moore QC 3rd, Norcross EW, Shafiee A, Marquart ME.

J Ocul Pharmacol Ther. 2010 Apr;26(2):193-8. doi: 10.1089/jop.2009.0121.

PMID:
20334537

Supplemental Content

Support Center